首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

亞太地區抗體藥物偶聯物市場預測至 2030 年 - 區域分析 - 按技術、應用和配銷通路

市場調查報告書

商品編碼

1481966

亞太地區抗體藥物偶聯物市場預測至 2030 年 - 區域分析 - 按技術、應用和配銷通路

Asia Pacific Antibody Drug Conjugates Market Forecast to 2030 - Regional Analysis - By Technology, Application, and Distribution Channel

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 101 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年亞太地區抗體藥物偶聯物市值為15.3283億美元，預計2030年將達到69.7103億美元；預計2022年至2030年複合年成長率為20.8%。

同意管理中對人工智慧的需求不斷成長，推動了亞太抗體藥物偶聯物市場的發展

癌症發生率上升主要導致對創新癌症治療的需求不斷增加。根據全球癌症觀察站 (GLOBOCAN) 2020 年發布的估計，全球有 1,930 萬癌症病例。中國和印度是癌症病例最多的國家之一。 GLOBOCAN 也估計，到 2040 年，印度的癌症病例將達到約 208 萬，比 2020 年成長 57.5% 。死於癌症。最常見的癌症類型是肺癌、乳癌、結腸癌和直腸癌、攝護腺癌和乳癌。癌症發生率的上升引起了全世界的關注。以下是 2020 年全球報告的常見癌症病例清單。

表 1. 2020 年全球新癌症病例

序號癌症類型病例數（百萬）

1胃1.09

2 皮膚（非黑色素瘤）1.2

3 前列腺 1.41

4 結腸和直腸 1.93

5 肺 2.21

6 乳房 2.26

癌症現在是一種生活方式疾病，常見於飲食習慣不健康和缺乏運動的人。此外，飲酒和吸煙也會增加罹癌的風險。低收入和中等收入國家的慢性傳染病可進一步加劇癌症危險因子。根據世界衛生組織2022年2月發布的資料，2018年診斷的人中近18％患有人類乳突病毒（HPV）、幽門螺旋桿菌、B型肝炎病毒、丙型肝炎病毒和EB病毒等慢性傳染病。

亞太地區抗體藥物偶聯物市場概況

亞太地區抗體藥物偶聯物（ADC）市場分為中國、日本、印度、韓國、澳洲和亞太其他地區。 ADC 市場的成長廣泛受到公司合作、癌症發生率上升和臨床試驗增加的推動。

亞太國家參與開發ADC的龍頭公司都有在研產品在完成臨床試驗後即將推向市場。 2023年6月，榮昌生物與信達生物簽署協議，進入臨床試驗並提供達伯舒（信迪利單抗注射液）與新型間皮素（MSLN）標靶抗體藥物偶聯物（ADC）RC88的聯合療法，或稱達伯舒 (TYVYT) 與 RC108，一種新型 c-Met 靶向 ADC。這些據稱是治療實體瘤的新療法。根據協議，榮昌生物將對達伯舒進行1/2a期臨床研究，以評估其抗腫瘤活性和安全性。該公司還有 Distamab vedotin (RC48) + PD1 組合正在研發中。此組合針對不同的癌症適應症分兩個階段進行評估，第一個組合處於III 期，評估用於治療尿路上皮癌，第二個組合處於II 期，評估用於治療肌肉浸潤性膀胱癌和胃癌。

此外，日本公司正在推出突破性產品，預計將主導 ADC 市場。 2021 年 6 月，第一三共株式會社和阿斯特捷利康公司推出了 Enhertu，這是一類新型 ADC，專為治療 HER2 低乳癌患者而開發。第一三共株式會社報告稱，以美國和歐洲銷售額計算，2023 年第一季銷售額年增 156.6%。該公司銷售額的如此巨大成長極大地促進了該國 ADC 市場規模的發展，預計未來幾年將呈指數級成長。

亞太地區抗體藥物偶聯物市場收入及 2030 年預測（百萬美元）

亞太地區抗體藥物偶聯物市場細分

亞太地區抗體藥物偶聯物市場根據技術、應用、配銷通路和國家進行細分。

根據技術，亞太地區抗體藥物偶聯物市場抗體藥物偶聯物市場分為可裂解接頭和不可裂解接頭。 2022 年，可切割連接子部分佔據了更大的佔有率。

根據應用，亞太地區抗體藥物偶聯物市場抗體藥物偶聯物市場分為血癌、乳癌、卵巢癌、尿路上皮癌等。 2022 年，乳癌細分市場所佔比重最大。

根據配銷通路，亞太地區抗體藥物偶聯物市場抗體藥物偶聯物市場分為醫院藥房、零售藥房和線上藥房。 2022年，醫院藥局部門佔最大佔有率。

依國家/地區分類，亞太地區抗體藥物偶聯物市場分為澳洲、中國、印度、日本、韓國和亞太地區其他地區。 2022年，日本在亞太抗體藥物偶聯物市場佔據主導地位。

輝瑞公司、羅氏公司、葛蘭素史克公司、吉利德科學公司、阿斯特捷利康公司、安斯泰來製藥公司、榮昌生物有限公司和武田製藥有限公司是亞太地區抗體藥物偶聯物市場的一些領先公司。

Rising cancer incidences are primarily leading to the increasing demand for innovative cancer treatments. As per the Global Cancer Observatory (GLOBOCAN) estimates published in 2020, there were 19.3 million cancer cases across the globe. China, and India were among the countries leading in cancer cases. The GLOBOCAN has also estimated that the cancer cases in India will be ~2.08 million by 2040, representing a rise of 57.5% from 2020. Similarly, as per the World Health Organization (WHO) data published in February 2022, ~10 million people have died from cancer. The most commonly seen cancer types were lung, breast, colon and rectum, prostate, and breast. The rising incidences of cancer have raised concerns worldwide. Below is the list of common cancer cases reported worldwide in 2020.

Table 1. New Cancer Cases Worldwide, in 2020

Sr. No. Cancer Type Number of Cases (Million)

1 Stomach 1.09

2 Skin (non-melanoma) 1.2

3 Prostate 1.41

4 Colon and Rectum 1.93

5 Lung 2.21

6 Breast 2.26

Cancer is now a lifestyle disease commonly seen among people with unhealthy food habits and who are physically inactive. Also, the consumption of alcohol and tobacco adds up to the risk of developing cancer. Chronic infectious diseases in low- and middle-income countries can further aggravate the cancer risk factors. According to the WHO data published in February 2022, chronic infectious diseases such as human papillomavirus (HPV), Helicobacter pylori, hepatitis B virus, hepatitis C virus, and Epstein-Barr virus attributed to nearly 18% of the diagnosed in 2018. Also, promising results of ADCs are anticipated to accelerate their demand as an effective cancer treatment and propel the market growth.

Asia Pacific Antibody Drug Conjugates Market Overview

The Asia Pacific antibody drug conjugates (ADCs) market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The growth of the ADCs market is widely driven by company collaborations, growing incidences of cancer, and increasing clinical trials.

The leading companies in Asia Pacific countries that are involved in developing ADCs have pipeline products to be launched in the market after completing the clinical trials. In June 2023, RemeGen Co., Ltd. signed an agreement with Innovent Biologics, Inc. to enter clinical trials and supply combination therapies TYVYT (sintilimab injection) with RC88, a novel mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), or TYVYT with RC108, a novel c-Met-targeting ADC. These are claimed to be novel therapies to treat solid tumors. Under the agreement, RemeGen Co., Ltd will conduct Phase 1/2a clinical studies for TYVYT to evaluate the anti-tumor activity and safety. The company also has Distamab vedotin (RC48) +PD1 combination in the pipeline. The combination is evaluated in two phases for different cancer indications, first combination is in phase III, evaluated to treat urothelial cancer in and second is in phase II, evaluated to treat muscle invasive bladder and gastric cancer.

In addition, Japanese companies are introducing breakthrough products that are expected to dominate the ADCs market. In June 2021, Daiichi Sankyo Company, Limited, and AstraZeneca plc launched Enhertu-a novel class of ADCs developed to treat HER2-low breast cancer patients. Daiichi Sankyo Company, Limited reported a year-on-year sales growth of 156.6% in the first quarter of 2023 by combining the US and European sales. Such a huge growth in the company's sales has significantly contributed to the ADCs market size in the country and is estimated to grow exponentially in the coming years.

Asia Pacific Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Antibody Drug Conjugates Market Segmentation

The Asia Pacific antibody drug conjugates market is segmented based on technology, application, distribution channel, and country.

Based on technology, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is bifurcated into cleavable linker and non-cleavable linker. The cleavable linker segment held a larger share in 2022.

Based on application, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. The breast cancer segment held the largest share in 2022.

Based on distribution channel, the Asia Pacific antibody drug conjugates market antibody drug conjugates market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share in 2022.

Based on country, the Asia Pacific antibody drug conjugates market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Japan dominated the Asia Pacific antibody drug conjugates market in 2022.

Pfizer Inc, Hoffmann-La Roche Ltd, GSK Plc, Gilead Sciences Inc, AstraZeneca Plc, Astellas Pharma Inc, RemeGen Co Ltd, and Takeda Pharmaceutical Co Ltd are some of the leading companies operating in the Asia Pacific antibody drug conjugates market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Market Attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics

4.1 Key Market Drivers:
- 4.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
- 4.1.2 Rising Incidences of Cancer Cases
- 4.1.3 Increasing FDA Approvals for ADCs
4.2 Market Restraints
- 4.2.1 High Cost of ADCs Development and Commercialization
4.3 Market Opportunities
- 4.3.1 Increasing Investments to Develop ADCs
4.4 Market Trends
- 4.4.1 Escalating Pipeline of ADCs
4.5 Impact Analysis:

5. Antibody Drug Conjugates Market - Asia Pacific Market Analysis

5.1 Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

6. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

6.1 Overview
6.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
6.3 Cleavable Linker
- 6.3.1 Overview
- 6.3.2 Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Non-cleavable Linker
- 6.4.1 Overview
- 6.4.2 Non-cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

7.1 Overview
7.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
7.3 Blood Cancer
- 7.3.1 Overview
- 7.3.2 Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Breast Cancer
- 7.4.1 Overview
- 7.4.2 Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Ovarian Cancer
- 7.5.1 Overview
- 7.5.2 Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Urothelial Cancer
- 7.6.1 Overview
- 7.6.2 Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
- 7.7.1 Overview
- 7.7.2 Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacies
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacies
- 8.4.1 Overview
- 8.4.2 Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
- 8.5.1 Overview
- 8.5.2 Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Antibody Drug Conjugates Market - Country Analysis

9.1 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 9.1.1 Overview
- 9.1.2 Asia Pacific Antibody Drug Conjugates Market Breakdown, by key Country - Revenue (2022) (US$ Million)
- 9.1.3 Asia Pacific: Antibody Drug Conjugates Market, by Country
  - 9.1.3.1 China
    - 9.1.3.1.1 Overview
    - 9.1.3.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.1.3 China: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.1.4 China: Antibody Drug Conjugates Market, by Application
    - 9.1.3.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.2 Japan
    - 9.1.3.2.1 Overview
    - 9.1.3.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.2.3 Japan: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.2.4 Japan: Antibody Drug Conjugates Market, by Application
    - 9.1.3.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.3 India
    - 9.1.3.3.1 Overview
    - 9.1.3.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.3.3 India: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.3.4 India: Antibody Drug Conjugates Market, by Application
    - 9.1.3.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.4 South Korea
    - 9.1.3.4.1 Overview
    - 9.1.3.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.4.4 South Korea: Antibody Drug Conjugates Market, by Application
    - 9.1.3.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.5 Australia
    - 9.1.3.5.1 Overview
    - 9.1.3.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.5.3 Australia: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.5.4 Australia: Antibody Drug Conjugates Market, by Application
    - 9.1.3.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
  - 9.1.3.6 Rest of Asia Pacific
    - 9.1.3.6.1 Overview
    - 9.1.3.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 9.1.3.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
    - 9.1.3.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
    - 9.1.3.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel

10. Asia Pacific Antibody Drug Conjugates Market-Industry Landscape

10.1 Overview
10.2 Organic Growth Strategies
- 10.2.1 Overview
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Companies' Manufacturing Capacities and Capabilities

11. Company Profiles

11.1 Pfizer Inc
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Hoffmann-La Roche Ltd
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Gilead Sciences Inc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 AstraZeneca Plc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Astellas Pharma Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 RemeGen Co Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Takeda Pharmaceutical Co Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Antibody Drug Conjugates Market Segmentation
Table 2. New Cancer Cases Worldwide, in 2020
Table 3. List of FDA-Approved ADCs
Table 4. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 5. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 6. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 7. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 8. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 9. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 10. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 11. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 12. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 13. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 14. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 15. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 16. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 17. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 18. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 19. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Technology
Table 20. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Application
Table 21. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn) - Distribution Channel
Table 22. Recent Organic Growth Strategies in Antibody Drug Conjugates Market
Table 23. Recent Inorganic Growth Strategies in the Antibody Drug Conjugates Market
Table 24. Glossary of Terms, Antibody Drug Conjugates Market

List Of Figures

Figure 1. Asia Pacific Antibody Drug Conjugates Market Segmentation, By Country
Figure 2. Key Insights
Figure 3. Asia Pacific Antibody Drug Conjugates Market - Key Industry Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030
Figure 6. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
Figure 7. Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Non-Cleavable Linker: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
Figure 10. Blood Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Breast Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Ovarian Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Urothelial Cancer: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Others: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Asia Pacific Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 16. Hospital Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Retail Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Online Pharmacies: Asia Pacific Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Antibody Drug Conjugates, by Key Country - Revenue (2022) (US$ Million)
Figure 20. Asia Pacific: Antibody Drug Conjugates Market, By Key Countries, 2022 And 2030 (%)
Figure 21. China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 24. South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 25. Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
Figure 26. Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)